The purpose of this study is to examine the effects of rapamycin (sirolimus) versus a
placebo, an inactive substance, on responses to smoking cues in individuals with nicotine
dependence. Rapamycin (sirolimus) is a FDA-approved antibiotic and immunosuppressive drug
that is currently used to (a) prevent organ transplant recipients from rejecting their
transplants (b) treat cardiovascular diseases, and (c) treat some forms of cancer. Rapamycin
(sirolimus) is not FDA-approved for smoking cessation. The use of rapamycin (sirolimus) in
this study is investigational, meaning that the study medication is not a proven treatment
for nicotine dependence, however this study will examine the medication's use as a potential
future treatment for nicotine dependence.